| abstract |
The invention relates to the use of compounds of general formula (I) wherein R<1> to R<5> are independently selected from the group consisting of hydrogen, branched and unbranched C1-C4--alkyl groups, branched and unbranched C1-C4--alkoxy groups, branched and unbranched C1-C4--alkythio groups, trifluoromethyl groups, C6-C10--aryloxy groups, C7-C11--aralkyloxy groups, C1-C5--acyloxy groups, C6-C10--aroyloxy groups, C1-C4--alkylsulfonyloxy groups, C6-C10--arylsulfonyloxy groups, linear and branched C1-C4--alkoxycarbonyl groups, amino, mono(C1-C5-Alkyl)amino and di(C1-C5--alkyl)amino groups, carbamoyl, N-mono(C1-C5--alkyl)carbamoyl and N-bi(C1-C5--alkyl)carbamoyl groups, methylene dioxy groups, hydroxy groups, hydroxymethyl groups, and fluorine and chlorine; R is selected from the group consisting of hydrogen and linear and branched alkyl groups; and (chin.) represents a 3-quinuclidinyl or a 2,3-dehydro-3-quinuclidinyl group, or the physiologically tolerable salts of said compounds, for producing a medicament against illnesses whereby stimulating the nicotinic acetylcholine receptors leads to an improvement in the clinical picture. |